Determining Energy Needs in Colorectal Cancer

Colorectal Cancer Clinical Trial

— RECODE  

Official title:

Resting Energy Expenditure in Cancer - Associations With Body Composition, Dietary Intake, and Exercise Habits

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03131921
• Other study ID #: HREBA.CC.15-0204
• Secondary ID: No grant number.
• Status: Completed
• Start date: April 5, 2016
• Est. completion date: August 18, 2022

Study information

• Verified date: August 2023
• Source: University of Alberta
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is an observational study to assess the determinants of energy expenditure in cancer, and how those change throughout the disease trajectory. The investigators hypothesize that skeletal muscle will be the primary determinant of energy expenditure throughout the disease trajectory.

Description:

Proper nutrition is a hallmark of successful cancer treatment. Adequate energy intake helps to maintain body weight and composition, improving outcomes such as response to therapy, quality of life, and survival. Unfortunately, little is known about energy needs in cancer, as few studies have assessed energy expenditure (the amount of calories used/day). Furthermore, individuals with cancer often experience muscle loss (sarcopenia), changes in physical activity, and undergo treatment, all of which might substantially alter energy needs. Equations to estimate energy REE (and thus dietary requirements) were created from cohorts of healthy individuals, and no tools that can be easily used in clinical settings are validated to assess REE.

The overarching aim of this study is to evaluate the largest component of energy needs - resting energy expenditure (REE) in relation to body composition (skeletal muscle, adipose tissue) and physical activity in a cohort of patients with colorectal cancer. Other aims will explore the changes in energy expenditure and determine the accuracy of a portable indirect calorimeter for measuring REE.

Newly-diagnosed individuals with stage II-IV colorectal cancer will undergo indirect calorimetry to assess REE. Body composition will be measured by CT scans, with sarcopenia status based on previously published cut-points. Nutritional status and inflammation (C-reactive protein, neutrophil:lymphocyte) will be assessed as confounding variables.

Total energy expenditure will be measured near treatment start in a sub-sample of 20 participants with colorectal cancer using doubly labeled water and accelerometers. Participants will wear accelerometers (ActiCal) for 14 days to provide detailed physical activity data.These assessments will also be preformed in a sub-sample of 20 participants after treatment end.

An additional part of this study will assess the validity of a portable indirect calorimeter for measuring REE. To address this, a sub-group of patients will be invited to undergo an additional test of REE using a portable indirect calorimeter, the FitMate (COSMED). Results will be compared using Pearson's correlation, dependent samples t-test, and Bland-Altman analysis to assess agreement between the FitMate and validated indirect calorimeters (VMax metabolic cart and whole body calorimtery unit). Exploratory outcomes include phase angle by bioelectrical impedance analysis, handgrip strength, calf circumference, and nutrition status by patient generated subjective global assessment (PG-SGA).

The results from this project will provide a basis of better energy recommendations to sustain body weight and composition, thereby improving prognosis in cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: August 18, 2022
• Est. primary completion date: August 18, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Pre-treatment Participants:

Inclusion Criteria:

• Recent diagnosis of colorectal cancer (stage II-IV);

• Able to arrive at the Human Nutrition Research Unit fasted;

• Patients undergoing treatment should be able to undergo measurements within 20 days of treatment commencement;

• Able to provide written informed consent;

• Able to communicate freely in English;

• Age 18-90

Exclusion Criteria:

• Recent (within the past month) anti-cancer therapy;

• Recent invasive surgery (within the last 4 weeks);

• Women during pregnancy or are breast-feeding;

• Inability to breathe under the indirect calorimeter hood for 20-30 minutes;

• Severe toxicity during the 1st cycle therapy (where applicable);

• Severe mobility issues (e.g. confined to wheelchair);

• Use of medications that may affect body composition or metabolism will be evaluated individually (e.g. cortico-steroids, hormone replacement, etc.)

• Patients with a pacemaker

Post-treatment participants:

Inclusion Criteria

• Recently (<3 year) completed adjuvant chemotherapy treatment for colorectal cancer (stage II-IV)

• Able to arrive at the Human Nutrition Research Unit fasted

• Able to provide written informed consent

• Able to communicate freely in English

• Age 18-90

Exclusion Criteria

• Recent (within the past month) anti-cancer therapy

• Recent invasive surgery (within the last 4 weeks)

• Women during pregnancy or are breast-feeding

• Inability to breathe under the indirect calorimeter hood for 20-30 minutes

• Severe mobility issues (e.g. confined to wheelchair)

• Use of medications that may affect body composition or metabolism will be evaluated individually (e.g. cortico-steroids, hormone replacement, etc.)

• Patients with a pacemaker

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Locations

Country	Name	City	State
Canada	Cross Cancer Institute	Edmonton	Alberta
Canada	University of Alberta	Edmonton	Alberta

Sponsors (2)

Lead Sponsor	Collaborator
University of Alberta	National Institutes of Health (NIH)

Country where clinical trial is conducted

Canada, 

References & Publications (6)

Kyle UG, Soundar EP, Genton L, Pichard C. Can phase angle determined by bioelectrical impedance analysis assess nutritional risk? A comparison between healthy and hospitalized subjects. Clin Nutr. 2012 Dec;31(6):875-81. doi: 10.1016/j.clnu.2012.04.002. Epub 2012 May 4. — View Citation

Moses AW, Slater C, Preston T, Barber MD, Fearon KC. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer. 2004 Mar 8;90(5):996-1002. doi: 10.1038/sj.bjc.6601620. — View Citation

Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008 Jul;9(7):629-35. doi: 10.1016/S1470-2045(08)70153-0. Epub 2008 Jun 6. — View Citation

Purcell SA, Elliott SA, Baracos VE, Chu QS, Prado CM. Key determinants of energy expenditure in cancer and implications for clinical practice. Eur J Clin Nutr. 2016 Nov;70(11):1230-1238. doi: 10.1038/ejcn.2016.96. Epub 2016 Jun 8. — View Citation

Reeves MM, Battistutta D, Capra S, Bauer J, Davies PS. Resting energy expenditure in patients with solid tumors undergoing anticancer therapy. Nutrition. 2006 Jun;22(6):609-15. doi: 10.1016/j.nut.2006.03.006. — View Citation

Skipworth RJ, Stene GB, Dahele M, Hendry PO, Small AC, Blum D, Kaasa S, Trottenberg P, Radbruch L, Strasser F, Preston T, Fearon KC, Helbostad JL; European Palliative Care Research Collaborative (EPCRC). Patient-focused endpoints in advanced cancer: criterion-based validation of accelerometer-based activity monitoring. Clin Nutr. 2011 Dec;30(6):812-21. doi: 10.1016/j.clnu.2011.05.010. Epub 2011 Jul 5. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Resting energy expenditure	To assess resting energy expenditure using indirect calorimtery	At baseline, before or immediately beginning cancer treatment
Secondary	Body composition	To assess skeletal muscle and adipose tissue using computerized tomography images taken before beginning cancer treatment	At baseline, before or immediately beginning cancer treatment
Secondary	Total energy expenditure	To assess total energy expenditure (one time, over 14 days) using doubly labeled water and accelerometers	Post-treatment, within 3 years after completion of cancer treatment